93 results
Causes of SVC Syndrome - Differential Diagnosis Framework
 • Benign (15-40%): Thrombosis (aka catheter-associated), Goiter, Fibrosing
Malignant (60-85%): SCLC ... , NSCLC, NHL, Germ
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Survival #EBM #Honc ... #Osimertinib #NSCLC ... #Survival #NEJM
Plasmacytomas and Plasma-Cell Leukemia - Physical examination revealed multiple exophytic subcutaneous lesions involving the arms and
stain) #Clinical #HONC ... #Derm #Plasmacytomas ... Leukemia #Smear #NEJM
Ecthyma Gangrenosum - A physical examination revealed a 2-cm hemorrhagic patch with an erythematous border (Panel
#Clinical #Derm ... #Honc #Ecthyma # ... #Neutropenic #NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Lung Cancer #EBM #Honc ... #ALKPositive #NSCLC ... VisualAbstract #NEJM
Early Events in Acute GVHD #Pathophys #Honc #GVHD #GraftVersusHostDisease #NEJM
GVHD #Pathophys #Honc ... GraftVersusHostDisease #NEJM
Possible Mechanisms Underlying Immune-Related Adverse Events #Pathophys #Honc #ImmuneRelatedAdverseEvents #Immunotherapy #NEJM
Events #Pathophys #Honc ... Immunotherapy #NEJM
The Pathway of Heme Synthesis, Showing Pathway Intermediates and End-Product Regulation by Heme #Pathophys #Honc #Heme
Heme #Pathophys #Honc ... Synthesis #Porphyria #NEJM
Managing long term side effects of chemotherapy #Management #Peds #Honc #Chemotherapy #SideEffects #Screening #Monitoring #BMJ
Managing long term ... Management #Peds #Honc
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
#EBM #Honc #PACIFIC ... #Durvalumab #NSCLC ... #NEJM